Wednesday 6th of February 2019

13:00-14:30             USG Workshop ( Hotel Novotel Centrum)
CHAIRS: Antonio Martorell- Calatayud (Spain), Ximena Wortsman (Chile)

13:00-13:30 Introducing the ultrasound in dermatology:re-discovering the hidradenitis suppurativa
Ximena Wortsman (Santiago, Chile)
13:30-14:00 Improving the medical management of hidradenitis suppurativa using ultrasound
Antonio Martorell-Calatayud (Valencia, Spain)
14:00-14:30 Role of ultrasound in the surgical management of hidradenitis suppurativa
Jorge Romani de Gabriel (Bercelona, Spain)
  *The practical trainings on USG in hidradenitis suppurativa will be offered to participants during next days of the Conference. Registration for practical trainings will be run at the Registration Desk. 
16:00-16:30                                   Opening Ceremony ( The Wroclaw Opera )
Jacek C. Szepietowski (Wroclaw, Poland)
President of the Conference 
Christos C. Zouboulis (Dessau, Germany)
President of EHSF
16:30-18:00 Plenary Session 
CHAIRS: Jacek C. Szepietowski (Poland), Christos C. Zoubulis (Germany), Gregor B.E. Jemec (Denmark) 
16:30-17:00 Misuse of psychoactive substances among patients with hidradenitis suppurativa                     
Amit Garg (New York, USA)
17:00-17:30 Biomarkers of hidradenitis suppurativa/acne inversa
Christos C. Zouboulis (Dessau, Germany)
17:30-18:00 Albert Neisser’s Lecture
Updated Medical treatments of hidradenitis suppurativa, more options, less evidence
Wayne Gulliver (St. John’s, Canada)
19:00 Welcome Reception in The Wroclaw Opera Foyer
  Hall A
  Thursday 7th of February 2019
8:30-9:00 EHSF General Assembly
9:00-10:30 Genetics 
CHAIRS: Evangelos Giamarellos-Bourboulis (Grece), Baoxi Wang (China)
9:00-9:15 Molecular profiling of hidradenitis suppurativa/acneinversa skin reveals immune related signatures influencing keratinocyte differentiation and innate immunity
André Nogueira da Costa (Brussels, Belgium)
9:15-9:30 DNA methylation and microRNA biomarkers for noninvasive detection of hidradenitis suppurativa
Uppala Radhakrishna (RoyalOak, USA)
9:30-9:45 In familial cases hidradenitis suppurativa occurs earlier and more severely in children than in parents
Philippe Guillem (Lyon, France)
9:45-10:00 In familial hidradenitis suppurativa, the gender of the parent who transmits the disease influences children’ phenotype
Philippe Guillem (Lyon, France)
10:00-10:15 MYH9: A newly identified mutation in 2 patients with steatocystoma multiplex suppurativa and their family members
Natalia Kirsten (Hamburg, Germany)
10:15-10:30 Discussion
10:30-11:00 Coffee break
11:00-12:30 Immunology 
CHAIRS: Errol Prens (The Netherlands), Aude Nassif (France)
11:00-11:15 Hidradenitis suppurativa is an auto-inflammatory disease: results of an ex vivo study
K.R. van Straalen (Rotterdam, The Netherlands)
11:15-11:30 The role of S100 proteins in hidradenitis suppurativa
Aleksandra Batycka-Baran (Wrocław, Poland)
11:30-11:45 The IL-1 path way is hyperactive in hidradenitis suppurativa and promotes skin infiltration and destruction
Kerstin Wolk (Berlin, Germany)
11:45-12:00 MAIT cells in hidradenitis suppurativa: friend or foe?
Catriona Gallagher (Dublin, Ireland)
12:00-12:15 Decreased serum level of interleukin-22 in patients with hidradenitis suppurativa
Małgorzata Ponikowska (Wrocław, Poland)
12:15-12:30 Discussion
12:30-14:00 Lunch break
14:00-15:30 Epidemiology 
CHAIRS: Veronique del Marmol (Belgium), Thrasyvoulos Tzellos (Nerway)
14:00-14:15 Hidradenitis suppurativa: disease burden on patients and the health care system in Germany - impact of severity and of duration of the disease
Uwe Kirschner (Mainz, Germany)
14:15-14:30 The Lithuanian prospective study of patients with hidradenitis suppurativa based on clinical outcomes proposed by ERN-Skin
Vesta Kucinskiene (Kaunas, Lithuania)
14:30-14:45 European registry for hidradenitis suppurativa (ERHS): state of play 2018
Mathilde Daxhelet (Brussels, Belgium)
14:45-15:00 Prevalence of hidradenitis suppurativa in German working population
Natalia Kirsten (Hamburg, Germany)
15:00-15:15 A retrospective study of the characteristics of patients with early-onset hidradenitis suppurativa
Philippe Guillem (Lyon, France)
15:15-15:30 Discussion
15:30-16:00 Coffee break
16:00-17:30 Medical Treatment 1 
CHAIRS: Vincenzo Bettoli (Italy), Angelo Marzano (Italy)
16:00-16:15 Intralesional triamcinolone for fistulous tracts in hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up
Jose C. Pascual (Alicante, Spain)
16:15-16:30 Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa - acne inversa in paediatric age: a prospective study
Vincenzo Bettoli (Ferrara, Italy)
16:30-16:45 Antiandrogens as a therapeutic option for hidradenitis suppurativa/acne inversa
Georgios Nikolakis (Dessau, Germany)
16:45-17:00 Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial
Hessel van der Zee (Rotterdam, Netherlands)
17:00-17:15 Addition of methotrexate to anti-TNF-a (infliximab or adalimumab) at induction treatment in severe hidradenitis suppurativa: improvement in therapeutic response and longer drug survival
Pierre-André Becherel (Antony, France)
17:15-17:30 Discussion
  Friday 8th of February 2019
9:00-10:30  Medical Treatment 2 
CHAIRS: Christos C. Zouboulis (Germany); Jean Revuz (France)
9:00-9:15  Intensification strategies 80 mg weekly with adalimumab in hidradenitis suppurativa: when and what for?
Fernando Alfageme (Majadahonda, Spain)
9:15-9:30  Efficacy of adalimumab in a patient with hidradenitis suppurativa and concomitant ulcerative colitis.
Marisol Contreras-Steyls (Malaga, Spain)
9:30-9:45  Effectiveness of secukinumab (anti-IL-17 monoclonal Ab) in hidradenitis suppurativa : an open study (17 cases)
Pierre-Andre Becherel (Antony, France)
9:45-10:00  Hidradenitis suppurativa successfully treated with ixekizumab – presentation of 2 cases
Natalia Kirsten (Hamburg, Germany)
10:00-10:15  Guselkumab in the treatment of severe hidradenitis suppurativa
Maximilian Kovacs (Darmstadt, Germany)
10:15-10:30  Discussion
10:30-11:00 Coffee break
11:00-12:30 Abbvie Satelite Symposium 
CHAIRS: Afsaneh Alavi (USA), Falk Bechara (Germany), Hessel van der Zee (The Netherlands) 
12:30-14:00 Lunch break
14:00-15:30 Surgical Treatment 
CHAIRS: Phlippe Guillem (France); Andrzej Bieniek (Poland)
14:00-14:15 Step by step surgery: a new therapeutic proposal for hidradenitis suppurativa
Mariano Suppa (Brussels, Belgium)
14:15-14:30 Wide surgical excision as treatment modality for hidradenitis suppurativa: a retrospective cohort study
Sree Ramu Suggu (Chandigarh, India)
14:30-14:45 Systematic review of complications and recurrences following surgical interventions in hidradenitis suppurativa
Gregor Jemec (Roskilde, Denmark)
14:45-15:15 Rare forms and complex surgical situations in patients with HS
Andrzej Bieniek & Falk Bechara (Wroclaw, Poland & Bochum, Germany)
15:15-15:30 Discussion
15:30-16:00  Coffee break
16:00-17:30  News from Clinical Trials 
CHAIRS: Jacek C. Szepietowski (Poland); Gregor B.E. Jemec (Denmark)
16:00-16:15 IFX-1 in patients with moderate to severe hidradenitis suppurativa /acne inversa (HS): baseline characteristics of a double-blind, randomized phase 2b dose-finding study (SHINE)
Evangelos J Giamarellos-Bourboulis (Athens, Greece)
16:15-16:30 Long term results from a phase 2a clinical study with IFX-1 in severe hidradenitis suppurativa
Evangelos J Giamarellos-Bourboulis (Athens,Greece)
16:30-16:45 Efficacy of adalimumab in moderate to servere hidradenitis suppurativa. Real life data
Angeles Arnandis-Muñoz (Valencia, Spain)
16:45-17:00 The impact of hidradenitis suppurativa on absenteeism, reduced productivity, and work disability. Results from the PIRANHA study.
Sylke Schneider-Burrus (Berlin, Germany)
17:00-17:15 Impact of adalimumab on stabilization or sustained improvement in disease activity in moderate to severe hidradenitis suppurativa patients: an integrated analysis of PIONEER I and II trials through 36 weeks
Amy E. Gamelli (Boston, USA)
17:15-17:30 Discussion
 17:30  -18:00 Closing Ceremony 
Jacek C. Szepietowski (Poland); Christos C. Zouboulis (Germany)
  Hall B
  Thursday 7th of February 2019
9:00-10:30   Burden 
CHAIRS: Łukasz Matusiak (Poland); Arnon D. Cohen (Israel)
9:00-9:15   High prevalence of psychological traumas in patients with hidradenitis suppurativa (HS)
Philippe Guillem (Lyon, France)
9:15-9:30   Indirect self-destructiveness in hidradenitis suppurativa patients
Amelia Głowaczewska (Wrocław, Poland)
9:30-9:45  Influence of proper diagnosis of hidradenitis suppurativa on patients daily life
Hans Bayer (Freiburg, Germany)
9:45-10:00   Sexual dysfunction in patients with hidradenitis suppurativa: prevalence and risk factors
Alejandro Molina-Leyva (Granada, Spain)
10:00-10:15  Quality of life in hidradenitis suppurativa patients’ partners: preliminary results
Katarzyna Włodarek (Wrocław, Poland)
10:15-10:30   Discussion
10:30-11:00 Coffee break
11:00-12:30 Outcome Measures 
CHAIRS: Hessel van der Zee (The Netherlands); Amit Garg (USA)
11:00-11:15 A composite biomarker score for the diagnosis of hidradenitis suppurativa
Evangelos Giamarellos-Bourboulis (Athens, Greece)
11:15-11:30 The initial development of HiSQOL: a hidradenitis suppurativa specific quality of life instrument
Linnea Thorlacius (Roskilde, Denmark)
11:30-11:45 QoL-HS - disease specific assessment of life in hidradenitis suppurativa
Natalia Kirsten (Hamburg, Germany)
11:45-12:00 Superscoring hidradenitis suppurativa
Mathieu Daoud (Brussels, Belgium)
12:00-12:15 Assessment of reliability of six commonly used scoring systems for hidradenitis suppurativa in a group of dermatology residents
Katarzyna Włodarek (Wrocław, Poland)
12:15-12:30 Discussion
12:30-14:00 Lunch break
14:00-15:30 Comorbidities 
CHAIRS: Wayne Gulliver (Canada); Skaidra Valiukevičienė (Lithuania)
14:00-14:15 Hidradenitis suppurativa comorbidities are similarly present in patients’ relatives and influence patients’ phenotype
Philippe Guillem (Lyon, France)
14:15-14:30 High prevalence of metabolic syndrome in patients with hidradenitis suppurativa, hospital-based study
Rositsa Lavcheva (Stara Zagora, Bulgaria)
14:30-14:45 Hidradenitis suppurative and ulcerative colitis, difficult treatment to control both pathologies at the same time
Veronica Monsalvez Honrubia(Madrid, Spain)
14:45-15:00 Hidradenits suppurativa and psychiatric disorders: the Florence experience
Francesca Prignano (Florence, Italy)
15:00-15:15 The treatment of hidradenitis suppurativa associated with SAPHO syndrome
Skaidra Valiukeviciene (Kaunas, Lithuania)
15:15-15:30 Discussion
15:30-16:00  Coffee break
16:00-17:30  Program in Hall A
  Friday 8th of February 2019
9:00-10:30 Innovative Research 
CHAIRS: Brian Kirby (Ireland); Lennart Emtestam (Sweden)
9:00-9:15 Deranged iron status in patients with hidradenitis suppurativa
Małgorzata Ponikowska (Wrocław, Poland)
9:15-9:30 Serum Vitamin D in hidradenitis suppurativa patients: a pilot study
Francesca Prignano (Florence, Italy)
9:30-9:45 Hidradenitis suppurativa in KID's syndrome: genetic characterisation, clinical and surgical intervention
Mayra Ianhez (Goiania, Brasil)
9:45-10:00 Combined transcriptomic and immunohistochemical analysis of hidradenitis suppurativa lesions shows IL-17A pathway engagement
Christian Loesche (Basel, Switzerland)
10:00-10:15 Cutaneous manifestations of the STAT1 mutation
Alba Sanchez Orta (Madrid, Spain)
10:15-10:30 Discussion
10:30-11:00  Coffee break
11:00-12:30     Program in Hall A
12:30-14:00    Lunch break
14:00-15:30  Imaging 
CHAIRS: Antonio Martorell-Calatayud (Spain); Ximena Wortsman (Chile)
14:00-14:15  Advances on ultrasound imaging of hidradenitis suppurativa
Ximena Wortsman (Santiago, Chile)
14:15-14:30  Hidradenitis suppurativa phenotypes based on clinical and ultrasound characteristics
Antonio Martorell (Valencia, Spain)
14:30-14:45  Color Doppler sonographic and epidemiological features of healing fistulous tracts in hidradenitis suppurativa patients treated with systemic and biological treatments
Fernando Alfageme (Majadahonda, Spain)
14:45-15:00  Teleultrasonography for the early diagnosis of hidradenitis suppurativa in the primary cares setting
Fernando Alfageme (Majadahonda, Spain)
15:00-15:15  Long-wave medical infrared thermography: a clinical biomarker of inflammation in hidradenitis suppurativa/acne inversa
Christos C. Zouboulis (Dessau, Germany)
15:15-15:30  Discussion
15:30-16:00  Coffee break
16:00-17:30 Program in Hall A
Conference program in PDF to download: here

Experimental Dermatology Supplement 2019 to download: